[Skip to Content]
Visit our RSS Feed View our RSS Feed
Bringing Health Information to the Community September 28th, 2020
CategoriesCategoriesCategories Contact UsContact Us ArchivesArchives Region/OfficeNNLM SearchSearch



Date prong graphic

FDA Office of Women’s Health (OWH) April 2019

Posted by on April 17th, 2019 Posted in: General, Multilingual

The The U.S. Food and Drug Administration approved the first treatment for postpartum depression. The FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD.

This approval marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option,” said Tiffany Farchione, M.D., acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research.  Read the full FDA News Release.

The OWH is celebrating National Minority Month. The FDA Office of Women’s Health offers free health fact sheets and brochures in multiple languages. You can download resources in over 15 languages.







Image of the author ABOUT Michelle Burda

Email author View all posts by
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services, National Institutes of Health, National Library of Medicine, under cooperative agreement number UG4LM012344 with the University of Utah, Spencer S. Eccles Health Sciences Library.​

NNLM and NETWORK OF THE NATIONAL LIBRARY OF MEDICINE are service marks of the US Department of Health and Human Services | Copyright | Download PDF Reader